Home › 2026-20427

Design and Safety Considerations for Clinical Trials Involving Ibogaine Drug Products; Request for Information

Read on FederalRegister.gov · Official PDF · Docket on Regulations.gov · Submit a comment · Add to calendar (.ics)

Summary (from the Federal Register abstract)

The Food and Drug Administration (FDA or the Agency) is describing the approaches it is considering for the design of early- phase clinical trials of ibogaine drug products and is opening a public docket to receive comments. The Department of Health and Human Services (HHS) is funding clinical development of ibogaine, and the first federally supported trials are expected to study ibogaine in adults with opioid use disorder (OUD) and adults with post-traumatic stress disorder (PTSD). FDA is building on the guidance for industry entitled "Psychedelic Drugs: Considerations for Clinical Investigations" by seeking comments, data, and information from the public on protocol elements relevant to ibogaine development--including dose selection and escalation, care setting, safety monitoring, eligibility criteria, stopping rules, and safety oversight, in part, because the Federal Government is funding work in this area. FDA will consider all information provided in response to this Request for Information (RFI) to inform whether and how these specific elements should be considered in its review of Investigational New Drug Applications (INDs) involving ibogaine.

Source: Federal Register API, document 2026-20427. Federal Register text is a U.S. government work. Confirm dates in the official document; later documents may extend, reopen or correct them.